Lee SH, et al. - Researchers performed this randomized crossover study to compare the pharmacokinetics (PKs) and evaluate the bioequivalence of 2 formulations of lenalidomide 25 mg [Lenalid 25 mg tablet (test formulation) and Revlimid 25 mg capsule (reference formulation)] in healthy subjects. They found similar PKs of the 2 formulations of lenalidomide 25 mg. For assuming bioequivalence with the reference formulation, the test formulation met the regulatory criteria.